Physician profile
Brian G Vikstrom
NPI 1285730820
$3,048.62
in general payments reported to CMS, 2019-2025
30 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.48 · 2021: $93.93 · 2022: $123 · 2023: $790 · 2024: $891 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729 · Education: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,728.59 |
| Education | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $435.03 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $312.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $294.29 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.44 | 2019-2025 | Iclusig, Fruzaqla, Entyvio |
| Eisai INC. | $173.12 | 2022-2025 | |
| Daiichi Sankyo INC. | $156.05 | 2023-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $154.24 | 2019-2024 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals Lp | $142.81 | 2023-2025 | Imfinzi, Calquence, Lynparza |
| Celgene Corporation | $116.90 | 2024-2025 | Reblozyl |
| Abbvie INC. | $109.89 | 2024-2025 | |
| Array Biopharma INC | $107.06 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Genentech USA, INC. | $88.70 | 2023-2024 | Tecentriq, Phesgo, Alecensa |
| Servier Pharmaceuticals LLC | $86.51 | 2023-2025 | |
| Genzyme Corporation | $73.43 | 2019-2023 | |
| Incyte Corporation | $68.04 | 2024-2025 | Jakafi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $63.01 | 2023-2024 | Imbruvica, Rybrevant, Darzalex |
| Beone Medicines USA, INC. | $62.18 | 2025 | Tevimbra |
| Glaxosmithkline, LLC. | $57.97 | 2025 | Ojjaara, Blenrep |
| Ipsen Biopharmaceuticals, INC | $50.32 | 2024-2025 | Onivyde |
| E.R. Squibb & Sons, L.L.C. | $46.89 | 2023-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $36.49 | 2024 | Padcev, Xtandi |
| Deciphera Pharmaceuticals INC. | $35.48 | 2025 | Romvimza, Qinlock |
| Bayer Healthcare Pharmaceuticals INC. | $34.85 | 2022 | |
| Seagen INC. | $30.07 | 2023 | |
| Beigene USA, INC. | $29.88 | 2025 | Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $24.91 | 2023 | Imbruvica, Epkinly |
| Sun Pharmaceutical Industries INC. | $24.71 | 2024 | |
| Gilead Sciences, INC. | $22.79 | 2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $19.07 | 2023 | Xarelto |
| Amgen INC. | $18.08 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Vikstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.